CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin Mohammed G. Maslub, Nur Aizati Athirah Daud, Mahasen A. Radwan, Abubakar Sha’aban & Arafa G. Ibrahim European Journal of Medical Research volume 29,...
1 This estimate was based largely on trials of moderate-intensity statin therapy. However, high-intensity atorvastatin (80 mg) has been shown to reduce CVD events more than moderate-intensity statins (atorvastatin [10 mg], pravastatin [40 mg], or simvastatin [20-40 mg]) in individuals with ...
The ASTEROID trial even showed regression of coronary atherosclerosis with very high-intensity statin therapy (Nissen et al., 2006). Similarly, Yu et al. showed that intensive but not regular-dose atorvastatin therapy resulted in regression of carotid atherosclerotic disease (Yu et al., 2007) and...
The concentration of ROS in the sample was quantified by its ability to inhibit the binding of the anti-ROS antibody to the immobilized ROS-BSA and subsequently the color intensity in the assay wells. The assay enabled the determination of ROS in plasma at concentrations as low as 40 pg/ml...
For statin-treated patients, the intensity of statin therapy was categorized as low intensity (simvastatin 10 mg, pravastatin 10–20 mg, or fluvastatin 20–40 mg), moderate intensity (atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–80 mg, pravastatin 40 mg, or fluvastatin 80 ...